Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva in Recurrent/Progressive Glioblastoma Multiforme
NCT00054496Phase 2Unknown
- Sponsor
- Cleveland Clinic
- Start
- Aug 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in glioblastoma multiforme (GBM), sponsored by Cleveland Clinic. Primary endpoint: Response Rate. Status: unknown.
02
Drugs
erlotinib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00054496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00054496.